2023
Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis
Mooring M, Yeung G, Luukkonen P, Liu S, Akbar M, Zhang G, Balogun O, Yu X, Mo R, Nejak-Bowen K, Poyurovsky M, Booth C, Konnikova L, Shulman G, Yimlamai D. Hepatocyte CYR61 polarizes profibrotic macrophages to orchestrate NASH fibrosis. Science Translational Medicine 2023, 15: eade3157. PMID: 37756381, PMCID: PMC10874639, DOI: 10.1126/scitranslmed.ade3157.Peer-Reviewed Original ResearchConceptsNonalcoholic steatohepatitisLiver inflammationNonalcoholic fatty liver diseaseProgression of NASHCysteine-rich angiogenic inducer 61Fatty liver diseaseLiver-specific knockout miceImproved glucose toleranceType 2 diabetesGlucose toleranceLiver diseaseNASH progressionProfibrotic macrophagesProinflammatory propertiesReduced fibrosisCardiovascular diseaseProfibrotic phenotypeFibrotic developmentKnockout miceNF-κBMetabolic diseasesNASH dietPDGFB expressionFibrosisProfibrotic program
2015
Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial
Monahan PE, Sun J, Gui T, Hu G, Hannah WB, Wichlan DG, Wu Z, Grieger JC, Li C, Suwanmanee T, Stafford DW, Booth CJ, Samulski JJ, Kafri T, McPhee SW, Samulski RJ. Employing a Gain-of-Function Factor IX Variant R338L to Advance the Efficacy and Safety of Hemophilia B Human Gene Therapy: Preclinical Evaluation Supporting an Ongoing Adeno-Associated Virus Clinical Trial. Human Gene Therapy 2015, 26: 69-81. PMID: 25419787, PMCID: PMC4326268, DOI: 10.1089/hum.2014.106.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, NeutralizingCapsidClinical Trials as TopicDependovirusDisease Models, AnimalDrug Evaluation, PreclinicalFactor IXGene ExpressionGenetic EngineeringGenetic TherapyGenetic VectorsHemophilia BHemorrhageHumansLiverMaleMiceMice, Inbred C57BLMice, KnockoutRecombinant ProteinsTailTissue DistributionVirionConceptsHuman clinical trialsClinical trialsVector deliveryDose-dependent inflammationAbility of adenoLiver infiltratesMacrovascular thrombosisHemophilic arthropathyClinical morbidityHistopathological findingsMice 8Mild hemophilia BHemophilic miceEfficacy profileNormal micePreclinical studiesIdentical dosesMarked tropismPreclinical evaluationClinical successFIX antibodyTail transectionFIX activityBiodistribution evaluationFunction variants
2008
Induced Hepatic Fibrosis in Rats: Hepatic Steatosis, Macromolecule Content, Perfusion Parameters, and Their Correlations—Preliminary MR Imaging in Rats
Kim H, Booth CJ, Pinus AB, Chen P, Lee A, Qiu M, Whitlock M, Murphy PS, Constable RT. Induced Hepatic Fibrosis in Rats: Hepatic Steatosis, Macromolecule Content, Perfusion Parameters, and Their Correlations—Preliminary MR Imaging in Rats. Radiology 2008, 247: 696-705. PMID: 18403622, DOI: 10.1148/radiol.2473070605.Peer-Reviewed Original Research